PEAK1 Promotes Prostate Cancer Progression and Docetaxel Resistance by Mediating the Polarization of Tumor-Associated Macrophages

Researchers investigated the role and mechanisms of pseudopodium-enriched atypical kinase (PEAK) 1 in prostate cancer progression and docetaxel resistance.